1 North Wealth Services LLC Sells 1,766 Shares of Johnson & Johnson $JNJ

Key Points

• 1 North Wealth Services LLC has significantly reduced its holdings in Johnson & Johnson by 64.3%, now owning just 980 shares valued at approximately $163,000.
• Johnson & Johnson reported $2.77 earnings per share (EPS) for the last quarter, exceeding expectations, with revenue of $23.74 billion, a 5.8% increase year-over-year.
• The company recently declared a quarterly dividend of $1.30 per share, resulting in an annualized yield of 2.9%.

1 North Wealth Services LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 64.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 980 shares of the company's stock after selling 1,766 shares during the period. 1 North Wealth Services LLC's holdings in Johnson & Johnson were worth $163,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its position in Johnson & Johnson by 0.5% in the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company's stock valued at $38,800,371,000 after acquiring an additional 1,170,120 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Johnson & Johnson by 0.4% in the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock valued at $5,131,723,000 after purchasing an additional 130,645 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Johnson & Johnson by 3.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company's stock worth $3,133,602,000 after purchasing an additional 712,181 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in Johnson & Johnson by 2.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock valued at $3,031,955,000 after purchasing an additional 448,666 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Citigroup raised their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a report on Thursday, August 21st. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Guggenheim reissued a "neutral" rating and set a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $176.29.

Johnson & Johnson Trading Down 0.3%

Shares of Johnson & Johnson stock traded down $0.57 during midday trading on Friday, reaching $178.20. The company had a trading volume of 9,733,095 shares, compared to its average volume of 8,970,201. The firm has a market cap of $429.15 billion, a PE ratio of 19.06, a P/E/G ratio of 2.27 and a beta of 0.40. The stock has a fifty day moving average price of $168.06 and a 200 day moving average price of $160.60. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.